Defibrillators

The FDA reinspected the St.

Paul, Minnesota, plant between November 9 and December 7.Boston Scientific still must resolve a second warning letter affecting other facilities.

The resolution of the FDA problems should put Boston Scientific in a better position to regain share in the market for implantable cardioverter They were up $1.13 at $16.14 in midday New York Stock Exchange trading - far off the $45-a-share levels they reached in 2004."The stock has been so beaten down and battered for so long, investors seem to be looking for any excuse to get involved at these levels," RBC Capital Markets analyst Phil Nalbone said.

Continued...

© Reuters 2007.

All Rights Reserved.

2 Next > FACT BOX ABT.N Last: Change: Up/Down: Quote Full Chart Company Profile Analyst Research Loading...

QUOTES by Name by S...

Read more...